RenovaCare (RCAR) Stock Price, News & Analysis

Company Overview

RenovaCare, Inc. is a clinical‐stage regenerative medicine company focused on developing and commercializing products for the treatment of severe skin injuries and chronic wounds. The company’s core technology, the TransForm™ device, is an autologous cell therapy system designed to harvest, process and deliver a patient’s epidermal cells directly to wound sites. By leveraging a proprietary vacuum technology, TransForm™ enables clinicians to create and apply a living skin spray that aims to accelerate healing in acute burns, diabetic foot ulcers and other complex skin defects.

RenovaCare holds a robust patent portfolio covering its TransForm™ platform, which it is advancing through clinical trials and regulatory pathways in the United States. The company’s research and development efforts are focused on validating the safety, efficacy and ease of use of its handheld device, with the goal of securing regulatory clearance for broader commercial use. RenovaCare’s product pipeline is complemented by ongoing preclinical studies to explore additional indications, including chronic wounds and dermatological conditions where enhanced skin regeneration could offer significant benefits.

Headquartered in Newport Beach, California, RenovaCare serves patients and healthcare providers in North America, with plans to expand into key international markets. The company collaborates with burn centers, wound care specialists and academic institutions to generate clinical data and refine treatment protocols. Through strategic partnerships and potential licensing arrangements, RenovaCare aims to establish a scalable manufacturing model and distribution network to support future product launches.

RenovaCare is led by CEO Klaus von Goetz, who brings over two decades of experience in medical device development and commercialization. Under his leadership, the company has built a multidisciplinary team of scientists, clinicians and regulatory experts dedicated to transforming wound care through regenerative medicine. RenovaCare’s mission is to deliver innovative therapies that restore skin integrity and improve patient outcomes in markets with significant unmet medical needs.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 4,600 shs
• Market Capitalization: $9 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RCAR Stock Analysis - Frequently Asked Questions

How do I buy shares of RenovaCare?

Shares of RCAR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of RenovaCare own?

Based on aggregate information from My MarketBeat watchlists, some other companies that RenovaCare investors own include Brainstorm Cell Therapeutics (BCLI), ReNeuron Group (RENE), Coherus Oncology (CHRS), Fulcrum Therapeutics (FULC), SCYNEXIS (SCYX) and Teva Pharmaceutical Industries (TEVA).

Company Calendar

• Today: 10/10/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Medical Equipment
• Current Symbol: OTCMKTS:RCAR
• CIK: 1016708
• Web: www.renovacareinc.com
• Phone: (888) 398-0202
• Fax: N/A
• Employees: 1
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: -134.19